Contribute Try STAT+ Today

Amid efforts to blunt rising medicines costs, a new analysis finds three states succeeded in helping their residents save money by capping out-of-pocket costs on pricey specialty drugs and, at the same time, also managed to avoid increased spending by health plans.

Overall, out-of-pocket spending by patients fell $351 per month in Delaware, Maryland, and Louisiana, each of which passed laws that set $150 caps on what consumers must pay for prescriptions for specialty medicines. These include medications to combat such hard-to-treat maladies as multiple sclerosis, rheumatoid arthritis, and hepatitis C, among others.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Once a patient reaches the cap, which entity absorbes the loss from the reduced co-pay contribution?

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy